SCHEMBL6791097

SCHEMBL6791097

COc1cc(C(=N)N)cc(OC)c1CN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 4/20 0.39
PLAU P00749 1/20 0.36
LTB4R Q15722 1/20 0.35
GRM2 Q14416 1/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
MTNR1A P48039 2/20 0.34
MTNR1B P49286 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK1 P28482 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
KLK1 P06870 1/20 0.33
KLK5 Q9Y337 1/20 0.33
ACHE P22303 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790938 0.85 RECQL (0.39) GRM2MEN1KMT2AMTNR1AMTNR1B
SCHEMBL26144388 0.84 PRSS1 (0.45) PRSS1PLAULTB4RMEN1ALDH1A1
SCHEMBL6650772 0.77 GPR35 (0.33) MEN1ALDH1A1KMT2AMTNR1AMTNR1B
SCHEMBL6792190 0.75 GRM2 (0.43) PRSS1GRM2
SCHEMBL26144389 0.74 ALDH1A1 (0.39) MEN1ALDH1A1KMT2AMTNR1AMTNR1B
SCHEMBL11893184 0.74 PRSS1 (0.48) PRSS1GRM2
SCHEMBL6650774 0.72 ABCB1 (0.35) MTNR1AMTNR1B
SCHEMBL18300233 0.72 TMPRSS15 (0.40) PRSS1GRM2
SCHEMBL26144387 0.72 RECQL (0.45) MEN1KMT2AMTNR1AMTNR1BCYP1A2
SCHEMBL6680663 0.71 ALDH1A1 (0.37) GRM2ALDH1A1MTNR1AMTNR1BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106626-A1 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade PHARMACIA CORPORATION 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106626-A1 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade TFPI, F2, TFPI2 PRSS1 68/4885PLAU 17/4885LTB4R 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.